Depomed (Nasdaq: DEPO) reports Q3 loss of $0.01 vs. the analyst estimate of ($0.15). Revenue for the quarter was $14.1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE